- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03539627
Azilsartan Medoxomil in Hypertensive pAtients With Stable Ischemic Heart Disease and DiabEtes MEllitus. (AcADEME)
One-center, Observational, Non-interventional, Prospective Study of the Efficacy of Azilsartan Medoxomil in Patients With Arterial Hypertension Associated With Stable Ischemic Heart Disease and Type 2 Diabetes Mellitus.
Study Overview
Status
Intervention / Treatment
Detailed Description
One-center, observational, non-interventional, prospective study of the efficacy of azilsartan medoxomil in patients with arterial hypertension associated with stable ischemic heart disease and type 2 diabetes mellitus.
During the study 5 visits to the research center are planned. At each visit, a physical examination, sampling of bio-samples for evaluation in the local laboratory, and collection of information on adverse events will be performed. 24-hours monitoring of blood pressure will be performed at screening, after 1 months of therapy and at the final visit (6 months of therapy).
Data will be collected during 5 consecutive visits to the research center. The observation period will be about 6 months, the active treatment period will be at least 6 months (24 weeks). Patients included in the study will be observed in an outpatient clinic according to the local practice of the research center.
It is planned that potentially eligible patients will be invited to the screening visit. Based on the results of daily monitoring of blood pressure, a final decision will be made about the suitability of the patient to participate in the study. Patients who have not reached the target values of blood pressure will start taking the study drug (Edarbi). By not achieving the target values of blood pressure, the mean daily systolic blood pressure is more than 130 mm Hg and the diastolic blood pressure is more than 90 mm Hg. The length of time between Visit 1 and Visit 2 is suspected to be no longer than 2 weeks.
All examinations (examination and evaluation of vital functions, laboratory tests, instrumental examinations) will be performed in accordance with the general standards of medical practice and in accordance with the routine practice of the institution.
Based on the number of patients hospitalized in the Research Institute For Complex Issues Of Cardiovascular Diseases (1500 patients), as well as the data on the prevalence of type 2 diabetes in this group (23.5%, 353 patients), the required sample size will be 184 patients (Confidence interval ± 5 %, the confidence probability is 95%).
SS = Z2 * (p) * (1-p) C2 where: Z = Z factor (1,96 for 95% confidence interval) p = percentage of respondents required, in decimal form (0,5 by default) c = confidence interval, in decimal form (for example, 0,04 = ±4%).
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Kemerovo, Russian Federation, 650002
- Anastasia Kochergina
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Informed consent signed by the patient.
- Men and women aged 18 years and older with a previously diagnosed hypertension and type 2 diabetes mellitus and stable ischemic heart disease.
- Stable therapy of hypertension, T2DM and ischemic heart disease for at least 12 weeks before screening.
Not achievement of target values * of blood pressure against the background of previously prescribed and steadily accepted antihypertensive therapy.
* not reaching the target figures of arterial pressure means mean systolic blood pressure more than 130 mm Hg and / or an average diastolic blood pressure more than 90 mmHg.
- Investigator's decision on the advisability of correction of previously prescribed therapy with the replacement of ACE inhibitors or other ARBs with azilsartan medoxomil.
Exclusion Criteria:
- Contraindications to the azilsartan medoxomil in accordance with instruction for use, including information on the individual intolerance of the drug.
- Any circumstances in the opinion of the investigator that interfere with the participation of the patient in the study.
- The patient included in the study is an employee of the center or a relative of the investigator.
- Participation in other clinical trials. Participation in register studies is allowed.
- Any disease or condition that leads to a decrease in the patient's life expectancy.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
patients with hypertension, CAD and diabetes
Patients with hypertension associated with stable CAD and diabetes on azilsartan medoxomil (Edarbi) therapy
|
patients are to receive azilsartan medoxomil
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Systolic blood pressure
Time Frame: interval: up to 24 weeks
|
Dynamics of clinical SBP from the baseline against the background of therapy with Edarbi®
|
interval: up to 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diastolic blood pressure
Time Frame: interval: up to 24 weeks
|
Dynamics of clinical DBP from the baseline against the background of therapy with Edarbi® (interval: Visit of inclusion - Visit 5);
|
interval: up to 24 weeks
|
Dynamics of renal function (filtration)
Time Frame: interval: up to 24 weeks
|
Dynamics of eGFR
|
interval: up to 24 weeks
|
Edarbi® efficacy
Time Frame: interval: up to 24 weeks
|
proportion of patients who respond to Edarbi® therapy (defined as decrease of SBP≥ 20 mm Hg or decrease of DBP≥10 mm Hg)
|
interval: up to 24 weeks
|
Dynamics of renal function (evidence of kidney injury)
Time Frame: interval: up to 24 weeks
|
N-GAL-dynamics
|
interval: up to 24 weeks
|
Dynamics of renal function (proteinuria detecton)
Time Frame: interval: up to 24 weeks
|
UACR dynamics
|
interval: up to 24 weeks
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Pain
- Neurologic Manifestations
- Endocrine System Diseases
- Coronary Disease
- Chest Pain
- Angina Pectoris
- Heart Diseases
- Coronary Artery Disease
- Myocardial Ischemia
- Hypertension
- Diabetes Mellitus
- Angina, Stable
- Molecular Mechanisms of Pharmacological Action
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Azilsartan medoxomil
Other Study ID Numbers
- IISR-2017-102380
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCCompletedType 2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
Clinical Trials on Azilsartan Medoxomil 40 MG Oral Tablet [Edarbi]
-
Hospital General de México Dr. Eduardo LiceagaUnknownHypertension | Obesity | Type 2 Diabetes MellitusMexico
-
TakedaCompleted
-
TakedaCompletedType 2 Diabetes Mellitus | Essential HypertensionTaiwan, Thailand, China
-
TakedaCompletedHypertensionUnited States, Mexico, Chile, Peru
-
University of ChicagoTakedaCompleted
-
TakedaCompletedHypertensionUnited States, Mexico, Argentina
-
TakedaCompletedHypertensionUnited States, Argentina, Peru, Mexico
-
Istituto Oncologico Veneto IRCCSCompletedGlioblastoma MultiformeItaly
-
TakedaCompletedEssential HypertensionChina
-
TakedaCompletedEssential HypertensionItaly, Poland, Spain, Bulgaria, Serbia, Netherlands, Estonia, Hungary, Germany, Sweden, Lithuania, Slovakia, United Kingdom, France